Multiply Labs

Executive Summary

Multiply Labs is transforming cell therapy manufacturing through its advanced robotic systems designed for industrial-scale production of gene-modified cell therapies. Founded in 2016 and based in San Francisco, the company's robots are compatible with leading GMP instruments, offering flexibility and scalability to address the critical manufacturing bottleneck in precision medicine. By building a comprehensive partner ecosystem, Multiply Labs aims to enable the life science industry to deliver personalized cell therapies to all patients, significantly reducing costs and improving accessibility. The company's technology has the potential to democratize advanced therapies and drive the next wave of innovation in drug delivery and digital health.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a Top-10 Pharma for Cell Therapy Manufacturing60% success
• Q4 2026Series B Funding Round ($30M+)70% success
• Q2 2026Launch of Next-Generation Robotic Platform for Allogeneic Therapies50% success